Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Genmab
Genmab
Genmab's blockbuster Darzalex surpasses $2B in sales
BioCentury
Tue, 01/8/19 - 11:40 pm
Genmab
Multiple Myeloma
Darzalex
Genmab and Johnson & Johnson’s Darzalex Dazzles in Multiple Myeloma Trial
BioSpace
Tue, 10/30/18 - 12:06 pm
JNJ
Janssen
Genmab
Darzalex
clinical trials
Multiple Myeloma
Genmab puts down $54M for immunotherapy collaboration — ready to spend millions more
Endpoints
Thu, 07/12/18 - 06:27 pm
Genmab
JNJ
Europe
cancer immunotherapy
Immatics
Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors
CP Wire
Thu, 07/12/18 - 09:17 am
Seattle Genetics
colorectal cancer
non-small cell lung cancer
pancreatic cancer
head and neck cancer
cervical cancer
tisotumab vedotin
Genmab
clinical trials
Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results
Xconomy
Tue, 05/29/18 - 11:36 am
clinical trials
Roche
Genentech
Genmab
JNJ
cancer
Tecentriq
Darzalex
Danish biotech Genmab hit by ending of trial using key cancer drug
Reuters
Mon, 05/28/18 - 01:35 pm
Genmab
JNJ
Janssen
Darzalex
Genmab hits roadblock in non-Hodgkin lymphoma
Biopharma Dive
Sat, 05/26/18 - 09:20 am
Genmab
non-Hodgkin's lymphoma
Arzerra
clinical trials
Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.
Fierce Pharma
Mon, 01/22/18 - 05:41 pm
Novartis
Arzerra
Genmab
CLL
chronic lymphocytic leukemia
Genmab and J&J 'love' partnership as some ponder takeover
Yahoo/Reuters
Thu, 11/30/17 - 09:42 am
Genmab
JNJ
M&A
Darzalex
Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort
Endpoints
Tue, 08/29/17 - 09:36 am
Seattle Genetics
Genmab
antibody-drug conjugate
tisotumab vedotin
Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger
Endpoints
Fri, 08/25/17 - 09:49 am
Genmab
daratumumab
Darzalex
Multiple Myeloma
clinical trials
Johnson & Johnson's 3 Biggest Sources of Growth Over the Next 10 Years
Motley Fool
Sat, 08/5/17 - 09:43 am
JNJ
devices
baby boomers
specialty medicines
M&A
Genmab
Imbruvica
Looking for Darzalex sales expansion, J&J, Genmab hit a wall in lymphoma
Fierce Pharma
Tue, 04/4/17 - 07:29 pm
Darzalex
JNJ
Genmab
non-Hodgkin's lymphoma
Johnson & Johnson May Already Have Its Remicade Replacement Well in Hand
Motley Fool
Sat, 02/25/17 - 03:21 pm
JNJ
Remicade
Darzalex
Genmab
Multiple Myeloma
Gilead licenses bi-specific tech from Danish biotech Genmab
BioPharma Dive
Sat, 08/13/16 - 02:38 pm
Gilead Sciences
Genmab
HIV
Novartis stops PhIII trial of Genmab's Arzerra after buying rights from GSK
Fierce Biotech
Fri, 03/11/16 - 10:36 am
Novartis
Genmab
Arzerra
GSK
pemphigus vulgaris
J&J nabs an early OK for 'breakthrough' multiple myeloma blockbuster contender Darzalex
Fierce Biotech
Mon, 11/16/15 - 03:29 pm
JNJ
Multiple Myeloma
daratumumab
FDA
Darzalex
Genmab
J&J positions blockbuster contender daratumumab for a multiple myeloma showdown
Fierce Biotech
Thu, 08/27/15 - 09:55 am
JNJ
daratumumab
Multiple Myeloma
Kyprolis
Amgen
Genmab
elotuzumab
AbbVie
Bristol-Myers Squibb
Novo Nordisk ties the R&D knot with Genmab, and they're not focused on cancer
Fierce Biotech
Fri, 08/14/15 - 11:20 am
Genmab
Novo Nordisk
R&D
Novartis files leukemia drug Arzerra in the EU
BioPharma Dive
Thu, 07/9/15 - 07:42 pm
Novartis
Arzerra
Europe
Genmab
CLL
chronic lymphocytic leukemia
Pages
« first
‹ previous
1
2
3
4
5
next ›
last »